Literature DB >> 11815561

Prescribing guidelines for severe Pseudomonas infections.

Helen Giamarellou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11815561     DOI： 10.1093/jac/49.2.229

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  16 in total

1.  Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infection.

Authors:  V Paul DiMondi; Mary L Townsend; Richard H Drew
Journal:  Int J Clin Pharm       Date:  2015-01-31

2.  Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.

Authors:  Yu Mi Wi; Kerryl E Greenwood-Quaintance; Audrey N Schuetz; Kwan Soo Ko; Kyong Ran Peck; Jae-Hoon Song; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Storage stability of inhalable phage powders containing lactose at ambient conditions.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Elizabeth Kutter; Sandra Morales; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2019-01-31       Impact factor: 5.875

4.  Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia.

Authors:  M P Crespo; N Woodford; A Sinclair; M E Kaufmann; J Turton; J Glover; J D Velez; C R Castañeda; M Recalde; D M Livermore
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

5.  Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy.

Authors:  Laura Pagani; Elisabetta Mantengoli; Roberta Migliavacca; Elisabetta Nucleo; Simona Pollini; Melissa Spalla; Rossana Daturi; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

6.  Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli.

Authors:  C-I Kang; J-H Song; W S Oh; K S Ko; D R Chung; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-04       Impact factor: 3.267

7.  Outer membrane protein I of Pseudomonas aeruginosa is a target of cationic antimicrobial peptide/protein.

Authors:  Yu-Min Lin; Shih-Jung Wu; Ting-Wei Chang; Chiu-Feng Wang; Ching-Shu Suen; Ming-Jing Hwang; Margaret Dah-Tsyr Chang; Yuan-Tsong Chen; You-Di Liao
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

8.  Antibiotic synergy interaction against multidrug-resistant Pseudomonas aeruginosa isolated from an abattoir effluent environment.

Authors:  Etinosa O Igbinosa; Emmanuel E Odjadjare; Isoken H Igbinosa; Phillips O Orhue; May N O Omoigberale; Napoleon I Amhanre
Journal:  ScientificWorldJournal       Date:  2012-04-26

9.  Vancomycin-Resistant Pseudomonas Aeroginosa in the Cases of Trauma.

Authors:  Koorosh Ahmadi; Amir Masoud Hashemian; Ehsan Bolvardi; Peyman Khadem Hosseini
Journal:  Med Arch       Date:  2016-01-31

10.  Pseudomonas bronchopulmonary infections in a palliative care setting.

Authors:  Naveen Salins; Nandini Vallath; Vv Prince
Journal:  Indian J Palliat Care       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.